Cancer Management Guidelines
-
Acute Myeloid Leukemia (AML)
Publications
Updated: September 2010
2010
-
Grimwade D, Hills RK, Moorman AV, Walker H, Chatters S, Goldstone AH, Wheatley K, Harrison CJ & Burnett AK. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood 116(3):354-365, 2010.
Grimwade 2010 Revised MRC cytogenetics classification for AML
2008
- Schlenk RF, Döhner K, Krauter J, Fröhling S, Corbacioglu A, Bullinger L, Habdank M, Späth D, Morgan M, Benner A, Schlegelberger B, Heil G, Ganser A, Döhner H. Mutations and Treatment Outcome in Cytogenetically Normal Acute Myeloid Leukemia. N Engl J Med 358:1909-18, 2008.
Schlenk 2008 NPM1 and FLT3 in German patients
Prior to 2008
- Burnett A, Milligan D, Prentice AG, Goldstone AH, McMullin MF, Hills RK, Wheatley K. A Comparison of Low-Dose Cytarabine and Hydroxyurea With or Without All-trans Retinoic Acid for Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome in Patients Not Considered Fit for Intensive Treatment. Cancer 109:1114-24, 2007.
Burnett 2007 ld ara-c cancer - Chalandon Y, Barnett MJ, Horsman DE, Conneally E, Nantel SH, Nevill TJ, Nitta J, Shepherd JD, Sutherland HJ, Toze CL, Hogge DE. Influence of Cytogenetic Abnormalities on Outcome after Allogeneic Bone Marrow Transplantation for Acute Myeloid Leukemia in First Complete Remission. Biol Blood Marrow Transplant 8:435-443, 2002.
Chalandon 2002 BBMT.8.8
| The information contained in these guidelines is a statement of consensus of Leukemia/BMT Program of BC professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient’s care or treatment. Use of these guidelines and documents is at your own risk and is subject to the Leukemia/BMT Program of BC’s terms of use available at Terms of Use. |